Dubois' Lupus Erythematosus and Related Syndromes
Elsevier - Health Sciences Division (Verlag)
978-0-323-47927-1 (ISBN)
- Titel erscheint in neuer Auflage
- Artikel merken
Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education.
Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients.
Offers an increased focus on the clinical management of related disorders such as Sjogren's syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS).
Presents the knowledge and expertise of more international contributors to provide new global perspectives on manifestations, diagnosis, and treatment.
Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, and more schematic diagrams throughout.
Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.
Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren's syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren's Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology. Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.
Preface, vii
List of Contributors, viii
SECTION 1 What Is Lupus?
1 History of Lupus, 1
2 Definition and Classification of Lupus and Lupus-Related
Disorders, 15
3 The Epidemiology of Lupus, 23
SECTION 2 Pathogenesis
4 Overview of Lupus Pathogenesis, 44
5 Genetics of Human SLE, 54
6 Epigenetics of Lupus, 69
7 The Environment and the Host, 86
8 The Innate Immune System in SLE, 93
9 B Cells and Generation of Antibodies, 101
10 T Cells, 116
11 Adaptive and Innate Immunoregulatory Cells, 125
12 Cytokines in Lupus, 137
13 Immunometabolism, 153
14 Animal Models in Lupus, 164
SECTION 3 Mechanisms of Tissue Injury
15 Abnormalities in Immune Complex Clearance and
Apoptotic Cell Clearance, 216
16 The Role of Complement in SLE, 224
17 Apoptosis and Inflammatory Forms of Cell Death, 237
18 Tissue Damage in Lupus: Free Radicals and Fibrosis, 248
19 Pathogenesis of Fibrosis-The Lung as a Model, 261
20 Pathogenesis of Lupus Nephritis, 269
21 Pathogenesis of Accelerated Atherosclerosis and
Vascular Injury in Systemic Lupus Erythematosus, 294
22 Pathogenesis of Cutaneous Lupus, 305
23 Pathogenesis of Neuropsychiatric Lupus, 317
24 Pathogenesis of Antiphospholipid Antibody
Syndrome, 324
25 Pathogenesis of Sjögren's, 338
SECTION 4 Autoantibodies
26 Structure and Derivation of Autoantibodies, 340
27 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes, 355
28 Antibodies Against ENA (Sm, RNP, SSA, SSB), 366
29 Antibodies Against C1q, 372
30 Antilipoprotein and Antiendothelial Cell
Antibodies, 375
31 Drug-Induced Lupus Erythematosus, 377
SECTION 5 Clinical Aspects of Lupus
Erythematosus
32 Overview and Clinical Presentation, 389
33 Skin Disease in Cutaneous Lupus Erythematosus, 395
34 The Musculoskeletal System and Bone
Metabolism, 407
35 Lupus and the Cardiopulmonary System, 418
36 Lupus and the Nervous System: Clinical Aspects, Psychopathology, and Imaging, 434
37 Gastrointestinal and Hepatic Systems, 457
38 Hematologic and Lymphoid Abnormalities in SLE, 473
39 Neonatal Lupus: Pathogenesis and Clinical
Approaches, 486
40 Pregnancy and Autoimmune Disease, Reproductive and
Hormonal Issues, 499
41 Systemic Lupus Erythematosus in Childhood and
Adolescence, 520
42 Clinical Aspects of Antiphospholipid Syndrome, 532
43 Lupus and Infections, 543
44 Ocular, Aural, and Oral Manifestations of Lupus, 556
45 Clinical Aspects of Sjögren's, 566
SECTION 6 Assessment of Lupus
46 Clinical Application of Serologic Tests, Serum Protein
Abnormalities, and Other Clinical Laboratory Tests in
Systemic Lupus Erythematosus, 579
47 Differential Diagnosis and Disease Associations, 598
48 Incomplete Lupus, Undifferentiated Connective Tissue
Disease, and Mixed Connective Tissue Disease, 606
49 Clinical Markers, Metrics, Indices, and Clinical
Trials, 614
50 Lupus Biomarkers, 631
SECTION 7 Management of Lupus
51 Principles of Therapy, Local Measures, and NSAIDs, 640
52 Antimalarial Medications, 650
53 Systemic Glucocorticoid Therapy for SLE, 661
54 Immunosuppressive Drug Therapy, 673
55 Complementary and Alternative Medications, Specialized and Niche Therapies, 689
56 Adjunctive Treatments and Preventive Measures, 702
57 Targeted Therapies in SLE, 710
58 Management of Cutaneous Lupus Erythematosus, 719
59 Epidemiology and Management of Lupus Nephritis, 727
60 Management of Sjögren's, 745
SECTION 8 Outcomes
61 Socioeconomic and Disability Aspects, 759
62 Prognosis and Mortality of SLE, 770
Index, 782
| Erscheinungsdatum | 17.10.2018 |
|---|---|
| Verlagsort | Philadelphia |
| Sprache | englisch |
| Maße | 216 x 276 mm |
| Gewicht | 2420 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Rheumatologie |
| ISBN-10 | 0-323-47927-8 / 0323479278 |
| ISBN-13 | 978-0-323-47927-1 / 9780323479271 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
